Biohaven reports Phase 1 activity of FGFR3‑directed ADC BHV‑1530 and plans pivotal trial in 2027

Biohaven presented Phase 1 data for its FGFR3‑directed antibody‑drug conjugate BHV‑1530 at the ENA 2026 symposium. Six of ten efficacy‑evaluable patients with FGFR3‑altered urothelial or HPV‑positive head‑and‑neck cancers achieved partial responses, and nine of ten showed tumour reduction. The drug was well tolerated with no dose‑limiting toxicities or treatment‑related serious adverse events among the 30 patients treated. Biohaven intends to start a pivotal study in FGFR3‑altered tumours, beginning as early as the first half of 2027, to seek accelerated approval.

The company says the pivotal trial could support an accelerated approval pathway, potentially bringing a first‑in‑class FGFR3‑directed ADC to market. If successful, the therapy could address an unmet need in patients who have progressed after standard urothelial cancer regimens, creating future revenue opportunities for Biohaven.

  • 1Six of ten efficacy‑evaluable patients with activating FGFR3 alterations treated at doses ≥3.3 mg/kg responded, including three of five with urothelial cancer and three of three with HPV‑positive head‑and‑neck cancer.
  • 2Nine of ten efficacy‑evaluable patients with activating FGFR3 alterations experienced tumour reduction.
  • 3No dose‑limiting toxicities, treatment‑related serious adverse events, or treatment‑related deaths were reported among the 30 patients as of the October 19 2026 data cutoff.
  • 4The most common adverse events were nausea (43%) and fatigue (37%), both Grade 1‑2.
  • 5Biohaven plans to initiate a pivotal study of BHV‑1530 in FGFR3‑altered tumours, starting as early as the first half of 2027, to support potential accelerated approval.
  • 6Biohaven completed an FDA Type C meeting in the fourth quarter of 2026.

Sources